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Abstract
Background: Lymphangiogenesis has become a new research frontier in tumor metastasis since
the discovery of reliable lymphatic markers that have allowed observation and isolation of
lymphatic endothelium. Cyclooxygenase-2 (COX-2) has been reported to be involved in the critical
steps in carcinogenesis. However, possible role of COX-2 in lymphangiogenesis and lymphatic
metastasis is still poorly understood. In present study, we aimed to investigate the relationship
between vascular endothelial growth factor-C (VEGF-C) and COX-2 in human breast cancer, and
correlations with lymphangiogenesis and prognosis.
Methods: Tissue samples of primary tumors from 70 patients undergoing intentionally curative
surgical resections for breast cancer were immunohistochemically examined for VEGF-C, COX-2,
and D2-40 expressions. The association between COX-2 and VEGF-C expressions and
clinicopathological parameters as well as prognosis were analysised. To demonstrate the presence
of proliferating lymphatic endothelial cells, 10 random cases with high LVD counts were selected
for D2-40/Ki-67 double immunostaining.
Results: A significant correlation was found between the expression of VEGF-C and COX-2 (r =
0.529, P < 0.001), and both elevated VEGF-C expression and elevated COX-2 expression were
associated with higher lymph vessel density (LVD), lymph node metastasis and D2-40 positive
lymphatic invasion (LVI) as well as worse disease free survival (DFS) and overall survival (OS) in a
univariate analysis. In the double immunostain for the lymph vessel marker D2-40 and the
proliferation marker Ki-67, the results confirmed Ki-67-positive nuclei in a proportion of lymph
vessel endothelial cells.
Conclusion: There is indeed lymphangiogenesis in breast cancer, the most compelling evidence
being the presence of proliferating lymphatic endothelial cells. VEGF-C and COX-2 are
coexpressed and significantly associated with lymphangiogenesis and prognosis in invasive breast
cancer. Suggesting COX-2 may up-regulate VEGF-C expression and thus promote lymph node
metastasis via lymphangiogenesis pathway in human breast cancer.
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Background
The lymphatic vasculature is an important route for the
metastatic spread of human cancer. And the presence of
tumour foci in lymph nodes is the most important
adverse prognostic factor in a variety of human cancers.
Recently, lymphangiogenesis, the formation of new lym-
phatic vessels, has become a new research frontier in
tumor metastasis since the discovery of the two major
lymphatic vessel growth factors-C (VEGF-C) and -D
(VEGF-D), as well as reliable lymphatic markers that have
allowed observation and isolation of lymphatic endothe-
lium[1]. VEGF-C, a member of the VEGF family, has been
shown to promote tumour lymphangiogenesis, the
spreading of tumour cells to lymph nodes in various ani-
mal models of cancer[2,3]. Furthermore, the elevation of
VEGF-C appears to correlate with lymph node metastasis
in numerous human cancers including breast cancer [4].
Cyclooxygenase-2 (COX-2), the inducible isoform of
prostaglandin H synthase, has been reported to be signif-
icantly overexpressed in a variety of human malignancies
including breast cancer, and was identified to be involved
in the critical steps in carcinogenesis [5-7]. However, pos-
sible role of COX-2 in lymphangiogenesis and lymphatic
metastasis is still poorly understood. Recently, it was
reported that COX-2 up-regulated VEGF-C and promotes
lymphangiogenesis in human lung adenocarcinoma[8]
and oesophageal adenocarcinoma [9,10] as well as in the
head and neck [11]. However, data is still scarce in breast
cancer and it is necessary to provide more documents to
increase the dataset.
In present study, we aimed to investigate the role of COX-
2 immunohistochemical expression in lymphangiogen-
esis, VEGF-C expression and D2-40 positive lymphatic
vessel invasion (LVI) as well as prognosis in a series of
archival human invasive breast cancer samples.
Methods
Patients and specimens
Paraffin-embedded archival specimens from 70 patients
with unilateral, invasive breast cancer, who were diag-
nosed and treated in the Department of Oncology, The
First Affiliated Hospital of Wenzhou Medical College,
from Januanry 2000 to October 2001, were included in
the study. We excluded patients with in situ carcinoma,
distant metastases at the time of the diagnosis, synchro-
nous or metachronous bilateral breast cancer, malignancy
other than breast cancer in history, and the patients who
had received neoadjuvant chemotherapy or radiation
therapy before surgery, which left 70 patients for the anal-
ysis. All patients had received mastectomy with dissection
of axillary lymph nodes, containing at least 10 nodes.
Routine histological examination was performed with
hematoxylin-eosin staining. All carcinomas were classi-
fied in accordance with the criteria of the World Health
Organization and were recorded as invasive ductal or
invasive lobular as well as invasive medullary-like carci-
nomas. The combined histological grade was obtained
according to a modified Scarff-Bloom-Richardson histo-
logical grading system with guidelines as suggested by
Nottingham City Hospital pathologists [12]. Tumor size
and lymph node status were evaluated separately. The
clinicopathological characteristics of the series are shown
in Table 1.
Immunohistochemistry
Sections (4 um) of paraffin-embedded tissue block were
rehydrated by sequential immersion in xylene, graded
ethanol and water, and then they were incubated in 3%
hydrogen peroxide methanol for 5 min, and followed by
using a microwave oven for antigen retrieval. After wash-
ing in phosphate-buffered saline (PBS), the slides were
exposure to 10% normal goat serum for 10 min to reduce
non-specific binding, this was followed by an overnight
incubation at 4°C in a humidified chamber with polyclo-
nal rabbit antihuman VEGF-C antibody (Zymed, USA) at
1:100 dilution, and monoclonal mouse antihuman COX-
2 antibody (Zymed, USA) at 1:100 dilution. The antigen-
antibody reaction was visualized by Picture Plus Kit
(Zymed, USA) and diaminobenzidine as the chromogen.
Finally, hematoxylin was used as a counterstain. Negative
controls were processed as above except for the primary
antibodies were used. Sections of colon cancer known to
express COX-2 and VEGF-C were used as positive controls.
A monoclonal mouse antihuman D2-40 antibody
(Zymed, USA) was used for the staining of lymphatic ves-
sels. The procedure of immunohistochemical staining of
D2-40 is similar to that of the COX-2 and VEGF-C staining
at a dilution of 1:100. And section from previously stud-
ied case of tonsilla known to express D2-40 was used as
the positive control.
To demonstrate the presence of proliferating lymphatic
endothelial cells, 10 random cases with high LVD counts
(above 50 percentile) were selected for D2-40/Ki-67 dou-
ble immunostaining. First, a monoclonal antibody
directed at Ki-67 (DakoCytomation; dilution 1:150) was
applied to the rehydrated paraffin sections for 30 minutes
after antigen retrieval in citrate buffer (pH 6.0) at 98°C.
Sections were incubated with EnVision+ Dual Link solu-
tion before development with diaminobenzidine (Dako-
Cytomation). Sections were then stained with the D2-40
antibody (Zymed; dilution 1:20) for 60 minutes. EnVi-
sion System alkaline phosphatase and Fast Red chro-
mogen (DakoCytomation) were used to visualize binding
of this second antibody.BMC Cancer 2008, 8:4 http://www.biomedcentral.com/1471-2407/8/4
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Evaluation of staining
The evaluation of staining were performed by two investi-
gators (Zhang and Li), who were unaware of the clinical
data or the disease outcome, examined all slides inde-
pendently. When the interpretation differed between the
two observers, slides were revaluated for a final decision at
a conference microscope.
For VEGF-C and COX-2 assessment, determination of the
intensity of the immunohistochemical staining was per-
formed according to Su et al.[8]. The immunostained sec-
tions were scanned by light microscopy, and all of the
tumor cells were evaluated: -, negative; +, focal expression
< 5% of cancer tissues; + +, focal expression in 5–20% of
cancer tissues; and + + +, diffuse expression > 20% of can-
cer tissues. The tissue with + + and + + + staining of COX-
2 or VEGF-C was classified as 'high expression group' and
those with - and + staining was assigned as 'low expression
group'.
Determination of lymphatic vessel density (LVD) was per-
formed as suggested by Weidner et al.[13]. The immunos-
tained sections were scanned by light-microscopy at low
magnification (40×) and the areas of tissue with the great-
est number of distinctly highlighted microvessels ('hot
spots') were selected. LVD was then determined by count-
ing all immunostained vessels at a total magnification of
(200×) from five areas for each case.
Determination of the staining reaction was strictly con-
fined to the 'hot spots' and the mean number of lymph
vessels in each case was evaluated. LVI was considered evi-
dent if at least one tumor cell cluster was clearly visible
inside the D2-40 stained vascular space [14].
Statistics
Spearman's coefficient of correlation, Chi-squared test,
and Mann-Whitney test were used as appropriate. Overall
survival (OS) curves and Disease free survival (DFS)
curves were obtained using the Kaplan-Meier method and
compared using the log-rank test. A multivariate model
Table 1: Correlation of clinicopathologic parameters with VEGF-C and COX-2 expressions.
VEGF-C Expression COX-2 Expression
Factor No. of cases Low High P value Low High P value
LVD 9.63 ± 5.09 12.83 ± 5.27 0.007a 9.17 ± 5.07 11.96 ± 5.32 0.012a
Age
≤ 50 40 23 17 0.944 12 28 0.383
> 50 30 17 13 12 18
Tumor size
≤ 2 2 81 81 0 0 . 3 2 4 1 01 8 0 . 8 3 7
>  2 4 22 22 0 1 42 8
Hisyological grade
G1 and G2 41 31 10 < 0.001 17 24 0.132
G 3 2 992 0 72 2
Lymph node metastasis
Positive 32 13 19 0.010 6 26 0.012
Negative 38 27 11 18 20
Histology
I D S ,  N O S 5 93 22 7 0 . 4 2 0 1 94 0 0 . 6 1 4
Others 11 8 3 5 6
ER
Positive 54 32 22 0.511 22 32 0.037
Negative 16 8 8 2 14
PR
Positive 46 27 19 0.716 19 27 0.087
Negative 24 13 11 5 19
c-erbB-2
Positive 13 6 7 0.375 2 11 0.205
Negative 57 34 23 22 35
LVI
Positive 25 10 15 0.031 4 21 0.016
Negative 45 30 15 20 25
a Analysis by Mann-Whitney U test.BMC Cancer 2008, 8:4 http://www.biomedcentral.com/1471-2407/8/4
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using the Cox stepwise regression analysis was used to
evaluate the statistical strength of independent associa-
tion between covariates and DFS and/or OS. For all tests,
a P-value less than 0.05 was considered to be significant.
All P-values given are results of two-sided tests.
Results
Clinical data
The median age at diagnosis for the 70 patients was 49
years (range, 30–77 years). 57.1% (n = 40) of the patients
were younger than 50 years, and 45.7% (n = 32) of the
patients had lymph node metastasis at the time of surgery
(Table 1). Median follow-up time for the 70 subjects was
68 months (range, 28–83 months). During this observa-
tion time, 20 patients developed recurrent disease, and 15
died from their cancer.
VEGF-C, COX-2 and D2-40 expression in human breast 
cancer tissues
Positive staining of both VEGF-C and COX-2 proteins was
seen in the cytoplasm of tumor cells (Fig 1a–b). However,
occasionally, normal epithelial cells and stromal compo-
nents showed faint staining, particularly adjacent stromal
endothelial cells for VEGF-C. High VEGF-C expression
was observed in 30 of 70 tumor samples (42.8%), while
high COX-2 expression occurred in 46 of the 70 tumor
samples (65.7%). D2-40 expression was essentially
restricted to thinwalled vessel-like structures. D2-40 posi-
tive lymphatic vessels were almost exclusively found
within the tumor stroma, at the tumor's invasion front
(Fig 1c). Occasional invasion of the carcinoma cells into
the lymph vessels was observed (Fig 1d). Median LVD
was11 microvessels/field (range, 3–26 vessels).
In the double immunostain for the lymph vessel marker
D2-40 and the proliferation marker Ki-67, the evaluation
of Ki-67 was performed according to Beasley et al.[15].
Positive staining of Ki-67 was seen in nuclei of lymphatic
endothelial cells (Fig 1e–f, black arrows). Proliferating
lymphatic endothelial cells were observed in 8 of the 10
cases analyzed. And, as expected, Ki-67-positive nuclei
were observed in the tumor cells themselves.
COX-2 expression correlated with VEGF-C level, lymph 
node metastasis and lymphatic vessel density
As showed in Table 2, there was a significant correlation
between COX-2 and VEGF-C protein expression of tumor
cells (P < 0.001, r = 0.529, Spearman's coefficient of cor-
relation).
The associations between VEGF-C and COX-2 expressions
and the clinicopathologic parameters are shown in Table
1. Both high expression of the VEGF-C and COX-2 were
correlated with the presence of lymph node metastasis (P
= 0.010, P = 0.012 respectively, both Chi-Square test) and
LVI (P = 0.031, P = 0.016 respectively, both Chi-Square
test). LVD was significantly higher in patients with high
expression of VEGF-C compared to patients with low
expression (P = 0.007, Mann-Whitney test), and there was
also a similar significantly association between LVD and
COX-2 expression (P = 0.012, Mann-Whitney test). Addi-
tionly, high expression of VEGF-C, but not of COX-2 was
correlated with advanced histological grading (P < 0.001,
Chi-Square test), and COX-2 expression was correlated
with ER status (P = 0.037, Chi-Square test). As showed in
Table 1, there was no significant association between
COX-2 expression and age (P = 0.383, Chi-Square test),
histological type (P = 0.614, Chi-Square test), size of pri-
mary tumor (P = 0.837, Chi-Square test), c-erbB-2 status
(P = 0.205, Chi-Square test) and PR status (P = 0.087, Chi-
Square test). Furthermore, a significant association
between LVI and LVD was found (P = 0.002, Mann-Whit-
ney test).
Survival analysis
Kaplan-Meier curves for survival are shown in Figure 2.
Patients with high expression of VEGF-C showed a signif-
icantly shorter DFS (P = 0.008, log-rank test, Fig 2a) and
OS (P = 0.014, log-rank test, Fig 2b) than patients with
low expression. Meanwhile, patients with high expression
of COX-2 was also found to have a significantly shorter
DFS (P = 0.009, log-rank test) and OS (P = 0.043, log-rank
test) than patients with low expression.
In Cox regression for DFS including patients'age, histolog-
ical grading, VEGF-C expression, histological type, tumor
size, LVD, lymph node metastasis, hormonal status, c-
erbB-2, LVI and COX-2 expression, only ER (P = 0.045),
LVI (P = 0.025), c-erbB-2 status (P = 0.007) and LVD (P =
0.015) remained as independent prognostic factors. How-
ever, based on multivariate Cox regression analysis for
OS, only c-erbB-2 status (P = 0.028) and LVD (P = 0.002)
were identified as the independent prognostic factors
(Table 3).
Discussion
COX-2 is a pleiotropic enzyme that mediates many phys-
iological functions in breast cancer progression such as
inhibition of cell apoptosis, increased cell motility, as well
as angiogenesis [5,7]. Costa et al.[16] reported that COX-
2 overexpression was significantly associated with lymph
node metastasis in human breast cancer. However,
whether COX-2 contributes to the formation of new lym-
phatic vessels is still little known. In the present study, ele-
vated COX-2 expression was positively correlated with
LVD and LVI. And the expression of COX-2 protein was
significantly higher in lymph node-positive group than in
the node-negative group. Which may suggest COX-2 pro-
mote the formation of lymphatic vessels and lymph node
metastasis. In addition, univariate analysis demonstratedBMC Cancer 2008, 8:4 http://www.biomedcentral.com/1471-2407/8/4
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that high COX-2 expression was negatively associated
with both DFS and OS. The result provides an explanation
that patients with high COX-2 expression were more
likely to have poor prognosis than low expression
patients, possibly resulting from COX-2-derived lym-
phangiogenesis in human breast cancer.
Research on tumor lymphangiogenesis has lagged behind
that of angiogenesis because of the lack of a specific lym-
phatic marker and the absence of detailed knowledge con-
cerning the molecular mechanisms of lymphangiogenesis
[1]. Recently, D2-40 antibody was reported to detect a fix-
ation-resistant epitope on a 40 kDa O-linked sialoglyco-
(a) : Breast cancer specimen with high vascular endothelial growth factor-C expression Figure 1
(a) : Breast cancer specimen with high vascular endothelial growth factor-C expression. Note the typical cytoplasmatic staining 
reaction, original magnification 400×. (b) : Breast cancer with high cyclooxygenase-2 expression. Typically granular staining was 
diffuse in cytoplasm of the cancer cells, original magnification 400×. (c) : D2-40-stained lymphatic vessel (arrows) with tumor 
cells (T) inside (lymph vessel invasion) was noted, original magnification 200×. (d) : Breast cancer specimen with a high peritu-
moral lymphatic vessel density (LVD), some of the lymphatic vessels stained for D2-40 are marked with arrows, original magni-
fication 200×. (e-f): Double staining for D2-40 (brown) and Ki-67 (red) of lymph vessels; Positive staining for Ki-67 is seen in 
nuclei of lymphatic endothelial cells (black arrows), original magnification 400×.BMC Cancer 2008, 8:4 http://www.biomedcentral.com/1471-2407/8/4
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protein expressed in lymphatic endothelium but not
blood vessels, and can be used to assess lymphangiogen-
esis specifically in conventionally processed formalin-
fixed and paraffin-embedded tissue specimens [17,18].
The present study clearly demonstrated that D2-40
reacted with the endothelium of lymphatic vessels, which
are covered with flattened endothelial cells, and does not
react with endothelial cells of blood vessels. Suggesting
D2-40 is a new selective marker of lymphatic endothelial
cells. In this study, D2-40 immunohistochemistry
revealed that lymph vessels were restricted to the endothe-
lium, almost exclusively in peri-tumoral lesions but not in
intra-tumoral lesions. Our results are consistent with pre-
viously reported studies [19-21], and might be explained
by a rising interstitial pressure caused by an increase in the
size of lesion or by the lack of intratumoral lymphangio-
genesis in breast cancer. Indicating that peritumoural lym-
phatic vessels are important for the process of metastatic
spread while intratumoural lymphatic vessels are non-
functional [21,22].
In the present study, we carried out double immunostain-
ing with antibodies to D2-40 and Ki-67 to observe the
occurrence of dividing nuclei among lymphatic endothe-
lial cells. The results confirmed Ki-67-positive nuclei in a
proportion of lymph vessel endothelial cells, suggesting
that there is indeed lymphangiogenesis in breast cancer,
the most compelling evidence being the presence of pro-
liferating lymphatic endothelial cells.
Experimental murine tumour models have demonstrated
a role for VEGF-C in tumour lymphangiogenesis and the
subsequent formation of lymph node metastasis [23].
Here we show that increased VEGF-C expression was asso-
ciated with lymph node metastasis, higher LVD and LVI in
human breast cancer. Our results suggest VEGF-C is a
potent enhancer of tumor lymphangiogenesis, leading to
increased metastatic spread of breast cancer cells to lymph
nodes. However, Kinoshita et al.[24] did not obtain a sig-
nificant association between VEGF-C expression and
lymph node metastasis. The difference between our find-
ings and those reported by Kinoshita et al.[24] may be due
to the use of different antibodies and the different number
of the cases as well as evaluation method of immunohis-
tochemistry.
In the present study, a significant association between
increased VEGF-C expression and advanced histological
grading was found, suggesting that poorly differentiated
tumor cells may be more capable to secrete VEGF-C,
which induced lymphangiogenesis in breast cancer.
The secretion of VEGF-C and VEGF-D by some tumours
could induce the activation of their receptor, VEGFR-3 on
the vascular endothelium and thereby inducing the for-
mation of new lymphatic vessels. However, little is cur-
rently known about the factors that make dome tumours
secret these lymphangiogenic factors [25]. In the present
study, a significant positive correlation between COX-2
and VEGF-C protein expression of tumor cells was seen,
which confirm to the previous studies [8-11,26], suggest-
Association of VEGF-C expression with patients'prognosis in  breast cancer (Kaplan-Meier method and log-rank test) Figure 2
Association of VEGF-C expression with patients'prognosis in 
breast cancer (Kaplan-Meier method and log-rank test). High 
VEGF-C expression was significantly related to recurrence 
(a, P = 0.008) and death (b, P = 0.014).
Table 2: Correlation between levels of cyclooxygenase-2 (COX-2) 
and vascular endothelial growth factor-C (VEGF-C) expression in 
human breast cancer.
COX-2a
VEGF-Ca -+2 + 3 + b
-b 46 4 1
+ 38 1 0 4
2+ 1 2 12 7
3+ 0 0 2 6
a Detection of the expressing level of COX-2 and VEGF-C by 
immunohistochemistry.
b Intensity of immunohistochemical staining.BMC Cancer 2008, 8:4 http://www.biomedcentral.com/1471-2407/8/4
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ing a lymphangiogenesis pathway that COX-2 may up-
regulate VEGF-C expression and thus the formation of
new lymphatic vessels in human breast cancer. However,
the correlation is much weaker compared with the result
reported by Timoshenko et al.[26] (correlation coeffi-
cients 0.553 vs 0.940). The discrepancy may be due to use
of different methods and different number of tumors
studied. For example, COX-2 and VEGF-C mRNA expres-
sion could also be observed in normal breast epithelium
[27,28], RT-PCR assay could not to reveal the two mole-
cules expression exactly if microdissection was not per-
formed, as well as the possibility that stromal cells and/or
immigrant leukocytes may also be the source of both mol-
ecules except for the breast cancer cells. Recently, HIF-1a
was also found to have a possible role in tumor lym-
phangiogenesis through the regulation of VEGF-C in
human esophageal cancer [29]. This suggests COX-2 is an
important, but not the only VEGF-C upstream regulator in
tumor lymphangiogenesis. COX-2 and VEGF-C expres-
sion should be examined in the context of other proposed
lymphangiogenic molecules such as HIF-1a in further
investigation.
Conclusion
Our study showed that COX-2 and VEGF-C may play an
important role in tumor metastasis. COX-2 may be up-
regulated by VEGF-C expression in order to promote lym-
phangiogenesis in human breast cancer. It is a considera-
ble speculation that a COX-2 inhibitor prevents lymph
node metastasis of breast cancer in clinical use.
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